cleminorexton

Preclinical

CCentessa Pharmaceuticals (UK) Limited

cleminorexton is one of 4 therapeutic programs targeting Narcolepsy Type 1. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Narcolepsy Type 1Recruiting

Narcolepsy Type 1Preclinical

Recruiting

Competition

Competitive Landscape

4 competitors in Narcolepsy Type 1

#DrugCompanyPhaseTrials

ALKS 2680 Dose 1

AAlkermes, Inc.

Phase 3

2 2

ALKS 2680 Dose 2

AAlkermes, Inc.

Phase 3

2 3

TAK-360

Takeda

Phase 2

1 4

cleminorexton

CCentessa Pharmaceuticals (UK) Limited

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalRecruiting

Narcolepsy Type 1

NCT07598708

Clinical

Trials by Indication[1]

Narcolepsy Type 11 trial

A Randomized, Double-blind, 3-Arm Parallel Design Study to Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Cleminorexton Compared With Placebo in Participants With Central Disorders of Hypersomnolence

Recruiting·CCentessa Pharmaceuticals (UK) Limited·Preclinical·NCT07598708·222 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for cleminorexton. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for cleminorexton. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Centessa Pharmaceuticals (UK) Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: CCentessa Pharmaceuticals (UK) Limited

cleminorexton

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Narcolepsy Type 11 trial

References

Drug Info

Quick Facts

Related News